Doyin Oluwole1, John Kraemer. 1. Pink Ribbon Red Ribbon, George W Bush Centre, 2943 SMU Boulevard, Dallas, Texas 75205, United States of America (USA).
Abstract
PROBLEM: In low- and middle-income countries, breast and cervical cancer have a poor prognosis, partly owing to barriers to treatment. To redress this situation, health systems must be strengthened. APPROACH: Pink Ribbon Red Ribbon (PRRR) is an innovative partnership designed to leverage public and private investments in global health and to build on the successful United States President's Emergency Plan for AIDS Relief (PEPFAR) platform to combat cancers of the breast and cervix in sub-Saharan Africa and Latin America. By supporting a comprehensive set of country-owned and country-driven interventions, PRRR seeks to reduce deaths from cervical cancer among women screened and treated through the programme and to reduce deaths from breast cancer by promoting early detection. LOCAL SETTING: In its initial phase, PRRR is supporting the governments of Botswana, Zambia and other countries in expanding cervical cancer prevention, screening and treatment coverage - especially to high-risk women with human immunodeficiency virus infection - and in strengthening breast cancer education and control services. RELEVANT CHANGES: PRRR has introduced a diagonal strategy based on the life course and continuum of care approaches to cancer control. Its work has resulted in the delivery of the human papillomavirus vaccine to young girls in several settings and in the strengthening of prevention, screening and treatment delivery systems from the community to the tertiary level. LESSONS LEARNT: This paper outlines the approach PRRR has taken as a country-aligned public-private partnership and the preliminary lessons learnt, including the need for flexible implementation, effective country coordination mechanism and regular communication with all stakeholders.
PROBLEM: In low- and middle-income countries, breast and cervical cancer have a poor prognosis, partly owing to barriers to treatment. To redress this situation, health systems must be strengthened. APPROACH: Pink Ribbon Red Ribbon (PRRR) is an innovative partnership designed to leverage public and private investments in global health and to build on the successful United States President's Emergency Plan for AIDS Relief (PEPFAR) platform to combat cancers of the breast and cervix in sub-Saharan Africa and Latin America. By supporting a comprehensive set of country-owned and country-driven interventions, PRRR seeks to reduce deaths from cervical cancer among women screened and treated through the programme and to reduce deaths from breast cancer by promoting early detection. LOCAL SETTING: In its initial phase, PRRR is supporting the governments of Botswana, Zambia and other countries in expanding cervical cancer prevention, screening and treatment coverage - especially to high-risk women with human immunodeficiency virus infection - and in strengthening breast cancer education and control services. RELEVANT CHANGES: PRRR has introduced a diagonal strategy based on the life course and continuum of care approaches to cancer control. Its work has resulted in the delivery of the human papillomavirus vaccine to young girls in several settings and in the strengthening of prevention, screening and treatment delivery systems from the community to the tertiary level. LESSONS LEARNT: This paper outlines the approach PRRR has taken as a country-aligned public-private partnership and the preliminary lessons learnt, including the need for flexible implementation, effective country coordination mechanism and regular communication with all stakeholders.
Authors: Mulindi H Mwanahamuntu; Vikrant V Sahasrabuddhe; Krista S Pfaendler; Victor Mudenda; Michael L Hicks; Sten H Vermund; Jeffrey S A Stringer; Groesbeck P Parham Journal: AIDS Date: 2009-03-27 Impact factor: 4.177
Authors: Wafaa M El-Sadr; Charles B Holmes; Peter Mugyenyi; Harsha Thirumurthy; Tedd Ellerbrock; Robert Ferris; Ian Sanne; Anita Asiimwe; Gottfried Hirnschall; Rejoice N Nkambule; Lara Stabinski; Megan Affrunti; Chloe Teasdale; Isaac Zulu; Alan Whiteside Journal: J Acquir Immune Defic Syndr Date: 2012-08-15 Impact factor: 3.731
Authors: Pragna Patel; Charles E Rose; Pamela Y Collins; Bernardo Nuche-Berenguer; Vikrant V Sahasrabuddhe; Emmanuel Peprah; Susan Vorkoper; Sonak D Pastakia; Dianne Rausch; Naomi S Levitt Journal: AIDS Date: 2018-07-01 Impact factor: 4.177
Authors: Renicha McCree; Mary Rose Giattas; Vikrant V Sahasrabuddhe; Pauline E Jolly; Michelle Y Martin; Stuart Lawrence Usdan; Connie Kohler; Nedra Lisovicz Journal: Oncologist Date: 2015-04-29
Authors: Sudha Sivaram; Michael A Sanchez; Barbara K Rimer; Jonathan M Samet; Russell E Glasgow Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-09-01 Impact factor: 4.254
Authors: Jeanine Condo; Brenda Kateera; Eugene Mutimura; Francine Birungi; Albert Ndagijimana; Stefan Jansen; Julius Kamwesiga; Jamie I Forrest; Edward J Mills; Agnes Binagwaho Journal: Trials Date: 2014-11-27 Impact factor: 2.279
Authors: Hari S Iyer; Racquel E Kohler; Doreen Ramogola-Masire; Carolyn Brown; Kesaobaka Molebatsi; Surbhi Grover; Irene Kablay; Memory Bvochora-Nsingo; Jason A Efstathiou; Shahin Lockman; Neo Tapela; Scott L Dryden-Peterson Journal: PLoS One Date: 2019-06-06 Impact factor: 3.752